Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma
- 1 January 2019
- journal article
- research article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 1105, 76-84
- https://doi.org/10.1016/j.jchromb.2018.12.008
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2017
- Elvitegravir for the treatment of HIVExpert Opinion on Pharmacotherapy, 2016
- The development and application of a novel LC–MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasmaJournal of Chromatography B, 2016
- Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infectionExpert Opinion on Drug Safety, 2015
- A liquid chromatography–tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasmaJournal of Chromatography B, 2014
- A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasmaJournal of Chromatography B, 2013
- Raltegravir as antiretroviral therapy in HIV/AIDSExpert Opinion on Pharmacotherapy, 2013
- The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing ProgramTherapeutic Drug Monitoring, 2011
- Quality Assurance Program for Pharmacokinetic Assay of Antiretrovirals: ACTG Proficiency Testing for Pediatric and Adult Pharmacology Support Laboratories, 2003 to 2004Therapeutic Drug Monitoring, 2006
- Therapeutic Drug MonitoringDrugs, 2003